1
|
Prevention effects of ND-07, a novel drug candidate with a potent antioxidative action and anti-inflammatory action, in animal models of severe acute pancreatitis. Eur J Pharmacol 2012; 687:28-38. [PMID: 22575522 DOI: 10.1016/j.ejphar.2012.04.048] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2012] [Revised: 04/17/2012] [Accepted: 04/21/2012] [Indexed: 12/17/2022]
Abstract
Oxidative stress and inflammation both play major roles in the development of the acute pancreatitis. Currently, a pancreatic enzyme inhibitor with limited efficacy is only clinically available in a few countries, and antioxidants or non-steroidal anti-inflammatory drugs (NSAIDs) provide only partial tissue protection in acute pancreatitis animal models. Here, we introduce a new drug candidate for treating acute pancreatitis named ND-07 [chemical name: 2-acetoxy-5-(2-4-(trifluoromethyl)-phenethylamino)-benzoic acid] that exhibits both potent antioxidative and anti-inflammatory activities. In an electron spin resonance (ESR) study, ND-07 almost blocked hydroxyl radical generation as low as 0.05 μM and significantly suppressed DNA oxidation and cell death in a lipopolysaccharide (LPS)-stimulated pancreatic cell line. In a cerulein plus LPS-induced acute pancreatitis model, ND-07 pretreatment showed significant tissue protective effects, with reductions of serum amylase and lipase levels and pancreatic wet weights. ND-07 not only diminished the plasma levels of malondialdehyde (MDA) and nitric oxide but also significantly decreased prostaglandin E₂ (PGE₂) and expression of tumor necrotizing factor-alpha (TNF-α) in the pancreatic tissue. In a severe acute necrotizing pancreatitis model induced by a choline deficient, ethionine-supplemented (CDE) diet, ND-07 dramatically protected the mortality even without any death, providing attenuation of pancreas, lung, and liver damages as well as the reductions in serum levels of lactate dehydrogenase (LDH), amylase and lipase, MDA levels in the plasma and pancreatic tissues, plasma levels of TNF-α, and interleukin-1 (IL-1β). These findings suggest that current dual synergistic action mechanisms of ND-07 might provide a superior protection for acute pancreatitis than conventional drug treatments.
Collapse
|
2
|
Caronna R, Loretta D, Campedelli P, Catinelli S, Nofroni I, Sibio S, Sinibaldi G, Chirletti P. Gabexate mesilate (FOY) inhibition of amylase and phospholipase A(2) activity in sow pancreatic juice. J INVEST SURG 2004; 16:345-51. [PMID: 14708545 DOI: 10.1080/08941930390250034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
We designed this study in sows to investigate the enzyme inhibitory action of gabexate mesylate (GM) directly in the pancreatic juice. We studied 16 sows, each weighing about 130 kg. The pancreatic duct was identified and cannulated to collect the pancreatic juice. Sows in the treated group received intravenous GM infusion at a dose of 1000 mg over 24 h. Control sows underwent the same sampling schedule while receiving physiological solution. GM inhibited the two pancreatic enzymes amylase and phospholipase A(2) (PA(2)) in pancreatic juice. Thus, the enzyme inhibition in the pancreatic gland itself and the central role of (PA(2)) inhibition in enzyme cascade responsible for activating other proteases confirm the therapeutic use of GM in acute pancreatitis.
Collapse
Affiliation(s)
- Roberto Caronna
- Dipartimento di Chirurgia "Pietro Valdoni", Universitá di Roma "La Sapienza", Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Hirata M, Hayashi I, Yoshimura K, Ishii KI, Soma K, Ohwada T, Kakita A, Majima M. Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats. Br J Pharmacol 2002; 135:29-36. [PMID: 11786477 PMCID: PMC1573123 DOI: 10.1038/sj.bjp.0704462] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
1. The involvement of bradykinin (BK) B(2) receptor in acute pancreatitis induced by pancreaticobiliary duct ligation was investigated in rats. 2. The activities of amylase and lipase in the serum, the water content of the pancreas, and vacuolization of the acinar cells were significantly increased 2 h after obstruction of the duct in Sprague-Dawley rats. 3. Elevated serum amylase activity, increased pancreatic oedema, and damage of the pancreatic tissue were significantly less marked in plasma kininogen-deficient, B/N-Katholiek rats than in the normal strain, B/N-Kitasato rats 2 h after the ligation. 4. Obstruction of the pancreaticobiliary duct augmented the level of (1-5)-BK (Arg(1)-Pro(2)-Pro(3)-Gly(4)-Phe(5)), a stable BK metabolite, in the blood from 73.0+/-21.7 pg ml(-1) at 0 h to 149.8+/-38.0 pg ml(-1) at 2 h after the induction of pancreatitis in SD rats. 5. Administration of a BK B(2) receptor antagonist, FR173657 (100 mg kg(-1), p.o.) or Hoe140 (100 nmol kg(-1), s.c.), reduced the elevation of amylase and lipase activities in the serum and of pancreatic water content in a dose-dependent manner. The effective attenuation of oedema formation and vacuolization by the antagonists was also confirmed light-microscopically. In contrast, treatment with gabexate mesilate or indomethacin did not cause significant suppression of the pancreatitis. 6. These findings suggest a possible involvement of kinin B(2) receptor in the present pancreatitis model. Furthermore, they point to the potential usefulness of the B(2) receptor in clinical acute pancreatitis.
Collapse
Affiliation(s)
- Mitsuhiro Hirata
- Department of Surgery, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
- Department of Traumatology and Critical Care Medicine, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
| | - Izumi Hayashi
- Department of Pharmacology, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
- Department of Molecular Pharmacology, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa 228-8555, Japan
- Author for correspondence:
| | - Kuniko Yoshimura
- Department of Traumatology and Critical Care Medicine, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
| | - Ken-ichiro Ishii
- Department of Surgery, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
| | - Kazui Soma
- Department of Traumatology and Critical Care Medicine, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
| | - Takashi Ohwada
- Department of Traumatology and Critical Care Medicine, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
| | - Akira Kakita
- Department of Surgery, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
| | - Masataka Majima
- Department of Pharmacology, Kitasato University School of Medicine, Kitasato, Sagamihara, Kanagawa 228-8555, Japan
- Department of Molecular Pharmacology, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa 228-8555, Japan
| |
Collapse
|
4
|
Di Giovannandre R, Diana L, Fiori M, Ferretti E, Foglietta G, Caronna R, Severini G. Determination of ethyl-p-hydroxybenzoate in sow pancreatic juice by reversed-phase high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2001; 751:365-9. [PMID: 11236093 DOI: 10.1016/s0378-4347(00)00477-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We have developed a high-performance liquid chromatographic-UV-Vis-diode-array detection (HPLC-DAD) method for the determination of ethyl-p-hydroxybenzoate, a hydrolytic degradation product of the synthetic protease inhibitor, gabexate-mesilate ethyl-p-(6-guanidinohexanoyloxy) benzoate methanesulfonate (GM) (FOY) in sow pancreatic juice. Methyl-p-hydroxybenzoate (I) was used as the internal standard. The pancreatic juice was deproteinised by acetonitrile and the analytes were chromatographed on a reversed-phase C18 LC column using the gradient elution method. The mobile phase consisted of a solution of 0.017 M orthophosphoric acid and another solution of acetonitrile-water (80:20, v/v). The wavelength of detection was 237 nm. The limit of quantification of the method was 0.20 microM at a 9:1 signal-to-noise ratio. The overall intra- and inter-day accuracy (relative error, RE) ranged from 14.2 to 8.3% and from 13.3 to 9.8, respectively. The overall intra- and inter-day precision (relative standard deviation, RSD) ranged from 7.6 to 2.62% and from 6.7 to 3.1%, respectively. The method proved to be sensitive, specific, accurate and precise and was successfully used to determine the ethyl-p-hydroxybenzoate (II) in sow pancreatic juice.
Collapse
Affiliation(s)
- R Di Giovannandre
- Istituto Superiore di Sanità, Laboratorio di Biochimica Clinica, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|